Connect your AI

Viking Therapeutics VKTX Revenue

Revenue at other companies

HTF

Heartflow, Inc. Common StockHTFL

$52.59M+41.3%

Cal-Maine FoodsCALM

$666.95M-53.0%

DJT

Trump Media & Technology GroupDJT

$871.2K+6.1%

ADMA BiologicsADMA

$114.49M-0.3%

Minerals TechnologiesMTX

$546.9M+11.2%

PhotronicsPLAB

$209.94M-0.5%

Other financials

Income statement

Revenue-—

Operating income-$164.1M-196%

Net income-$158.3M-247%

EPS (diluted)-$1.37-234%

Balance sheet

Cash & equivalents$118.1M+211%

Total debt$137.0K-87.8%

Total equity$501.9M-40.7%

Total assets$608.2M-29.8%

Cash flow

Operating cash flow-$114.0M-118%

Valuation

Market cap$4.04B+38.7%

Returns & leverage

Return on equity-70%-94.5pp

Debt / equity0×0.0×

Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Viking Therapeutics's revenue?: Viking Therapeutics (VKTX) reported revenue of $0 in Q1 2026.